Synopsis

With more than 49 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 9th RSC/SCI symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes as well as successful past programmes.

Programme Themes

This event will bring together industrial and academic experts representing many of the leading institutions in kinase drug discovery, to discuss a selection of new and emerging topics within the fields of kinase therapeutics for oncology and non-oncology therapies, and foster discussions within the wider industry through networking and industrial exhibitions.

Who should attend

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

Registration

Registration is open and fees are:

£75 RSC or SCI member*
£100 Non-member
£35 RSC or SCI student** member
£50 Student** non-member

* Member is paid-up member of the RSC or SCI.
** Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.

Exhibitor Opportunities

We are offering an Exhibitor Sponsorship Package to our valued supporters. This comprises:
- Your name and weblink on our event webpage
- Your logo in the rolling slides shown at the event and a web-linked logo in the electronic delegate handbook
- An A4 promotional page in the electronic delegate handbook

Charge is £150 (excludes delegate registration)

Sponsorship

We are grateful to our confirmed sponsors

AstraZeneca
MSD INVENTING FOR LIFE
charles river
evotec
SYGNATURE DISCOVERY
Domainex Enrich your medicines pipeline



Secretariat Contact

RSC BMCS Secretariat, Maggi Churchouse, UK,
+44 (0)1359 221004, **maggi@maggichurchouseevents.co.uk**

Websites

https://www.maggichurchouseevents.co.uk/bmcs
https://www.rscbmcs.org/events and www.soci.org/events



Third Announcement

Image generated from PDB Code: 5A9U, X-ray crystal structure of Lorlatinib bound to ALK. Shaw et al., N. Engl. J. Med. 374 (1), 54-61 (2016)

Kinase 2021

9th RSC / SCI symposium on kinase inhibitor design

Wednesday & Thursday, 14th & 15th April 2021

A virtual event

Organised by:
RSC Biological and Medicinal Chemistry Sector and
SCI Fine Chemicals Group

RSC INTEREST GROUP
BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR

SCI where science meets business

#Kinase21

Kinase 2021

9th RSC / SCI symposium on kinase inhibitor design

Programme

Wednesday, 14th April

Session 1	Session co-chairs: **Mihiro Sunose**, Sygnature Discovery, and **Pascal Savy**, Charles River, UK
14.00	Opening remarks
14.05	*The shape-shifting protein kinases* **Peter Parker**, Francis Crick Institute, UK
14.35	*Use of NanoLuc®-derived bioluminescent tools for live-cell target engagement and PROTAC-mediated degradation of kinases* **Craig Malcolm**, Promega, UK
14.40	*Design and evaluation of novel heterocyclic cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors* **Kirsten McAulay**, CRUK Beatson Institute, UK
15.10	Refreshment break
Session 2	Session co-chairs: **Douglas Williamson**, Vernalis Research, and **Ray Finlay**, AstraZeneca, UK
15.25	*Discovery of potent and selective Nuak1 inhibitors* **Karine G Poullennec**, UCB Biopharma, Belgium
15.55	*Prep HPLC from Teledyne ISCO: Taking the hard work out of method development with our focused gradient generator* **Lisa Sargeant**, Teledyne ISCO, USA
16.00	*Fragment-derived, selective and orally-active inhibitors of DYRK1A and DYRK1B* **Lee Walmsley**, Vernalis Research, UK
16.30	Closing remarks

Programme (continued)

Thursday, 15th April

Session 3	Session co-chairs: **John Harris**, CJH Consultants, and **Hannah Woodward**, University College London, UK
14.00	*Opening remarks*
14.05	*Discovery of potent TTBK1 inhibitors that lower tau phosphorylation in vivo for the treatment of Alzheimer's disease* **Toma Halkina**, Biogen, USA
14.35	*Enhanced kinase discovery and validation using TMT® proteomics* **Ian Pike**, Proteome Sciences, UK
14.40	*Protein degradation of kinases with PROTACs: a route to differentiated medicines?* **John Harling**, GlaxoSmithKline, UK
15.10	Refreshment break
Session 4	Session co-chairs: **John Cumming**, F Hoffman-La Roche, Switzerland, and **Sarah Major**, Evotec, UK
#15.25	*Exploiting the kinase conformational repertoire for allosteric regulation of IRE1a kinase-endoribonuclease* **Ian Collins**, The Institute of Cancer Research, UK
15.55	*Activate Scientific: chemistry services for drug discovery* **Declan Wolverson**, Activate Scientific, UK
16.00	*Highly selective DDR1 Inhibitors from efficient screening and structure-guided design* **Bernd Kuhn**, F Hoffmann-La Roche, Switzerland
16.30	*Closing remarks*

Sponsors

We are grateful to our sponsors for their kind support of this event.

AstraZeneca

MSD INVENTING FOR LIFE

Domainex Enrich your medicines pipeline

charles river

evotec

SYGNATURE DISCOVERY